Form 4: Edgewise Therapeutics Director Acquires Shares
Statement of Changes in Beneficial Ownership
Jonathan C. Fox, a Director at Edgewise Therapeutics, Inc., reported the acquisition of 339 shares of common stock on April 1, 2026, as part of a quarterly retainer award.
Summary
- Jonathan C. Fox, a Director of Edgewise Therapeutics, Inc., acquired 339 shares of common stock on April 1, 2026.
- This acquisition was made as a Quarterly Retainer Award under the company's Outside Director Compensation Policy.
- The shares were acquired at no cost ($0.00).
- Following this transaction, Mr. Fox beneficially owns 24,514 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine compensation-related stock acquisition by a director rather than a significant strategic event or financial performance indicator.
Positives
- Director acquisition of shares can signal confidence in the company's future prospects.
- The acquisition was part of a standard compensation package for directors, indicating ongoing engagement.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to a director's stock acquisition.
Industry Context
StockSavvy.ai notes that director stock awards are a common practice in the biotechnology and pharmaceutical sectors, aligning executive and director interests with those of shareholders. This type of filing is routine for monitoring insider activity.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation Policy | Acquisition of shares by Director Jonathan C. Fox as a Quarterly Retainer Award pursuant to Section 2.4 of the Edgewise Therapeutics, Inc. Outside Director Compensation Policy, as amended. | 04/01/2026 | Confirms adherence to the established director compensation structure. |
Related Party Transactions
- The acquisition of 339 shares by Director Jonathan C. Fox is a transaction between the company and its director, executed under the terms of the Outside Director Compensation Policy.
Stakeholder Impact
- Shareholders: The acquisition by a director may be viewed positively as a sign of continued commitment, though the impact is minimal given it's part of a compensation plan.
- Employees: No direct impact.
- Management: Reinforces the compensation structure for the board.
- Creditors: No direct impact.
Key Dates
| Date | Description |
|---|---|
| 04/01/2026 | Date of earliest transaction and acquisition of common stock by Director Jonathan C. Fox. |
| 04/03/2026 | Date of signature for the filing. |
Keywords
Edgewise Therapeutics, EWTX, Form 4, Director Compensation, Stock Acquisition, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.